Indian CRDMOs Poised to Gain from U.S. Biosecure Act Shift

With the U.S. Senate passing the Biosecure Act restricting Chinese biotech firms, Indian contract research and manufacturing organizations are emerging as strategic alternatives in global supply chains. Despite challenges like high capital costs and regulatory delays, India’s $3–3.5 billion CRDMO industry could triple to $22 billion by 2030 amid rising global outsourcing.